The Immunogenicity of CpG, MF59-like, and Alum Adjuvant Delta Strain Inactivated SARS-CoV-2 Vaccines in Mice

被引:2
|
作者
Xu, Kangwei [1 ]
Li, Jing [2 ]
Lu, Xu [1 ]
Ge, Xiaoqin [2 ]
Wang, Kaiqin [1 ]
Wang, Jiahao [2 ]
Qiao, Zhizhong [1 ]
Quan, Yaru [1 ]
Li, Changgui [1 ]
机构
[1] Natl Inst Food & Drug Control, NHC Key Lab Res Qual & Standardizat Biotech Prod, NMPA Key Lab Qual Res & Evaluat Biol Prod, 2 Tiantan Xili, Beijing 100050, Peoples R China
[2] Sinovac Life Sci Co Ltd, Daxing Biomed Ind Base Zhongguancun Sci Pk, 21 Tianfu St, Beijing 100050, Peoples R China
基金
北京市自然科学基金;
关键词
SARS-CoV-2; inactivated vaccines; Delta; immunogenicity; adjuvants;
D O I
10.3390/vaccines12010060
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The continuous evolution and mutation of SARS-CoV-2 have highlighted the need for more effective vaccines. In this study, CpG, MF59-like, and Alum adjuvant Delta strain inactivated SARS-CoV-2 vaccines were prepared, and the immunogenicity of these vaccines in mice was evaluated. The Delta + MF59-like vaccine group produced the highest levels of S- and RBD-binding antibodies and live Delta virus neutralization levels after one shot of immunization, while mice in the Delta + Alum vaccine group had the highest levels of these antibodies after two doses, and the Delta + MF59-like and Delta + Alum vaccine groups produced high levels of cross-neutralization antibodies against prototype, Beta, and Gamma strain SARS-CoV-2 viruses. There was no significant decrease in neutralizing antibody levels in any vaccine group during the observation period. CpG, MF59-like, and Alum adjuvant Delta strain inactivated SARS-CoV-2 vaccines excited different antibody subtypes compared with unadjuvanted vaccines; the Delta + CpG vaccine group had a higher proportion of IgG2b antibodies, indicating bias towards Th1 immunity. The proportions of IgG1 and IgG2b in the Delta + MF59-like vaccine group were similar to those of the unadjuvanted vaccine. However, the Delta + Alum vaccine group had a higher proportion of IgG1 antibodies, indicating bias towards Th2 immunity. Antigen-specific cytokine secretion CD4/8+ T cells were analyzed. In conclusion, the results of this study show differences in the immune efficacy of CpG, MF59-like, and Alum adjuvant Delta strain inactivated SARS-CoV-2 vaccines in mice, which have significant implications for the selection strategy for vaccine adjuvants.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies
    Kandeil, Ahmed
    Mostafa, Ahmed
    Hegazy, Rehab R.
    El-Shesheny, Rabeh
    El Taweel, Ahmed
    Gomaa, Mokhtar R.
    Shehata, Mahmoud
    Elbaset, Marawan A.
    Kayed, Ahmed E.
    Mahmoud, Sara H.
    Moatasim, Yassmin
    Kutkat, Omnia
    Yassen, Noha N.
    Shabana, Marwa E.
    GabAllah, Mohamed
    Kamel, Mina Nabil
    Abo Shama, Noura M.
    El Sayes, Mohamed
    Ahmed, Amira N.
    Elalfy, Zahraa S.
    Mohamed, Bassim M. S. A.
    Abd El-Fattah, Safa N.
    El Hariri, Hazem Mohamed
    Abdel Kader, Mona
    Azmy, Osama
    Kayali, Ghazi
    Ali, Mohamed A.
    VACCINES, 2021, 9 (03) : 1 - 15
  • [22] Evaluation of Immunogenicity of an Inactivated SARS-CoV-2 Vaccine Prototype in vitro
    Hancharou, Andrei
    Antonevich, N.
    Pozniak, T.
    Babrukevich, Darya
    Semizhon, P.
    Scheslenok, E.
    Rynda, A.
    Timohina, O.
    Minich, Y.
    DuBuske, Lawrence
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB96 - AB96
  • [23] Protection from infection or disease? Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines
    Anthony T.Tan
    Joey Ming Er Lim
    Antonio Bertoletti
    Virologica Sinica, 2022, (06) : 783 - 785
  • [24] Protection from infection or disease? Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines
    Anthony TTan
    Joey Ming Er Lim
    Antonio Bertoletti
    Virologica Sinica, 2022, 37 (06) : 783 - 785
  • [25] Immunogenicity profiling and distinct immune response in liver transplant recipients vaccinated with SARS-CoV-2 inactivated vaccines
    Duan, Binwei
    Zhang, Gongming
    Wang, Wenjing
    Yin, Jiming
    Liu, Mengcheng
    Zhang, Jing
    Chen, Dexi
    Ouyang, Yabo
    Li, Guangming
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [26] Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines
    Han, Xuexiang
    Alameh, Mohamad-Gabriel
    Butowska, Kamila
    Knox, James J.
    Lundgreen, Kendall
    Ghattas, Majed
    Gong, Ningqiang
    Xue, Lulu
    Xu, Ying
    Lavertu, Marc
    Bates, Paul
    Xu, Junchao
    Nie, Guangjun
    Zhong, Yi
    Weissman, Drew
    Mitchell, Michael J.
    NATURE NANOTECHNOLOGY, 2023, 18 (09) : 1105 - +
  • [27] Protection from infection or disease? Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines
    Tan, Anthony T.
    Lim, Joey Ming Er
    Bertoletti, Antonio
    VIROLOGICA SINICA, 2022, 37 (06) : 783 - 785
  • [28] Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV
    Lv, Zhengchao
    Li, Qin
    Feng, Zaixiong
    Zheng, Xi
    Yin, Na
    Yang, Haihao
    Gu, Qianlan
    Ying, Sai
    Qi, Yan
    Li, Xiaosi
    Wu, Runfang
    Wu, Zhao
    Yu, Xiyu
    Zou, Nanting
    Qin, Dongdong
    Wan, Chunping
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 102
  • [29] Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines
    Xuexiang Han
    Mohamad-Gabriel Alameh
    Kamila Butowska
    James J. Knox
    Kendall Lundgreen
    Majed Ghattas
    Ningqiang Gong
    Lulu Xue
    Ying Xu
    Marc Lavertu
    Paul Bates
    Junchao Xu
    Guangjun Nie
    Yi Zhong
    Drew Weissman
    Michael J. Mitchell
    Nature Nanotechnology, 2023, 18 : 1105 - 1114
  • [30] Safety of inactivated SARS-CoV-2 vaccines in patients with allergic diseases
    Cao, Chao
    Qiu, Feng
    Lou, Chengcheng
    Fang, Lingling
    Liu, Fang
    Zhong, Jingjing
    Sun, Weijie
    Ding, Weiping
    Yu, Xiaopin
    Xu, Qinhong
    Wang, Ran
    Ruan, Liemin
    Song, Qifa
    RESPIRATORY RESEARCH, 2022, 23 (01)